English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62629
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorOcaña, Alberto-
dc.contributor.authorPandiella, Atanasio-
dc.identifierdoi: 10.1038/nrclinonc.2010.194-
dc.identifierissn: 1759-4774-
dc.identifiere-issn: 1759-4782-
dc.identifier.citationNature Reviews Clinical Oncology 8: 200-209 (2011)-
dc.description.abstractMolecular-targeted agents are increasingly used for the treatment of cancer. However, the attrition rate for drugs that enter early clinical trials is higher than for other branches of internal medicine, suggesting that preclinical development has not been successful in identifying agents that can modify the outcome of human cancer. New preclinical strategies including genetically engineered mouse models and small-interfering RNAs are being used to evaluate novel agents, and have aided in the development of compounds, such as inhibitors of phosphatidylinositol 3-kinase or poly(ADP-ribose) polymerase. In addition, these techniques have helped in the identification of promising combinations of targeted drugs. In this Review, we describe methods for the preclinical evaluation of novel agents, their limitations, and strategies for improvement. © 2011 Macmillan Publishers Limited. All rights reserved.-
dc.publisherNature Publishing Group-
dc.titlePreclinical development of molecular-targeted agents for cancer-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.